The drug Enhertu (trastuzumab deruxtecan) has recently become available for women with untreatable breast cancer in the UK, bringing new hope to thousands of women. This drug can extend patients' lives by up to three years and represents a significant shift in attitude from public health officials, as it was previously stated that the drug was not cost-effective.
Changes in Drug Policies
The drug Enhertu, which treats a type of breast cancer known as HER2-low, has been available in Scotland and 26 European countries since 2023. Recent changes in trade agreements with the United States and a shift in how the economic value of drugs is measured have led to this surprising decision. Health officials announced that this drug could be considered as a first-line treatment option for patients with this type of breast cancer.
Emotional Implications for Patients and Families
This decision has been interpreted as good news for patients and their supporters, although some view it as bittersweet. Clare Roney, Executive Director of Breast Cancer Now, said: "Today we can say we have succeeded." However, she also pointed out that "we cannot celebrate this important decision without remembering the devastating costs of this delay." This delay meant the loss of many lives, and families were severely impacted.
More than 1000 women with advanced HER2-low breast cancer can access the drug Enhertu starting today. This type of breast cancer occurs when cancer cells have low levels of the HER2 protein. While this drug is also used for HER2-positive breast cancer, which is a fast-growing type.
In presentations at the American Society of Clinical Oncology conference in Chicago, the positive impact of this drug on patients was clearly evident. The average increase in lifespan for patients with HER2-low breast cancer has been seven months, but in some cases, women can live up to three years longer.
Yvette Cooper, the Health Secretary, commented on today's approval: "Enhertu can be life-changing, and this recommendation means that NHS patients can finally benefit from it." She also acknowledged the ongoing efforts of advocates and charities who never ceased to push for access to this treatment.
Helen Knight, Director of Drug Evaluation at NICE, expressed satisfaction that this drug is now available, but noted that this decision "has affected many families far too late." She added: "Our role in ensuring that NHS costs for new drugs reflect their benefits is very important."
Dr. Anne Reig, consultant oncologist and national NHS England chemotherapy advisor, described the news as "very positive" and stated that this decision gives women the opportunity to spend more time with their loved ones. She emphasized the importance of this decision for women and families affected.
